Dosing 

Recommended dose: 1.0 mg/kg⁵

• Mix calculated volume with 50 mL of sterile 0.9% sodium chloride solution.
• Administer via a peripheral or central vein over a 15-minute period.

Standard course of therapy: 5 doses⁵

• Administer first dose no more than 24 hours before transplantation.
• Administer four remaining doses at intervals of 14 days.

No dosage adjustment is necessary for these patients:⁵

• With severe renal impairment
• Based on other identified covariates (age, gender, proteinuria, race)

ZENAPAX® (daclizumab) is not for direct injection⁵

• Dilute in 50 mL of sterile 0.9% sodium chloride solution before intravenous administration.

• When mixing, gently invert the bag in order to avoid foaming; DO NOT SHAKE. Care must be taken to assure sterility, since the drug product does not contain any antimicrobial preservative or bacteriostatic agents.

• ZENAPAX is a colorless solution provided as a single-use vial; any unused portion should be discarded. Inspect visually for particulate matter and discoloration before administration. If particulate matter is present or the solution is colored, do not use.

• Once infusion is prepared, administer within 4 hours. If it must be held up to 24 hours, refrigerate between 2^o and 8^o C (36^o to 46^o F). After 24 hours, the prepared solution should be discarded.

  Safety Information

 

Reference:

⁵ZENAPAX® [product information]. Nutley, NJ: Roche Laboratories Inc.; September 2005.